公司资料
Passage Bio 股价、新闻与催化剂
- 股票代码:
- PASG
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.04 USD (+3.70%)
收盘价
最后更新: 2026年9月17日
18.9M USD
市值
股价为何变动
截至 2026年9月17日，PASG 上涨 3.70%，收于 $5.04。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Passage Bio is a gene-therapy company focused on rare and neurological diseases. Its business has centered on the challenge of translating genetic medicine into the central nervous system.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Passage sits in advanced biotechnology.
商业模式特征
The company depends on clinical data, delivery science, and the ability to create value in rare genetic disease.
生物医药行业定位
Passage is a high-catalyst gene-therapy name whose valuation is tied to early clinical outcomes.
未来催化剂
- Passage Bio’s catalysts are its rare-CNS gene-therapy programs and any strategic update that clarifies which assets still matter. The company needs stronger clinical clarity.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。